Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

A new method of treating wounds after major trauma costing nearly £150 per dressing is no more effective in reducing surgical infection rates than a standard wound dressing priced under £2, potentially saving the NHS millions.

Op-site dressing at laparotomy wound applied immediately to the patient after surgery. © Shutterstock

Major trauma is where a patient suffers injuries to several different parts of their body at the same time or very serious injuries to just one part. Worldwide, it is the leading cause of death in people under 45 years and a significant cause of short and long-term disability. Major trauma is commonly associated with serious limb injuries such as fractured bones, but treatment of these fractures is complicated because the soft-tissues around the bone are also badly damaged. Serious wound healing complications such as deep infection are therefore common.

The type of dressing applied over the wound at the end of the operation may reduce the risk of infection. Negative pressure wound therapy (NPWT), which involves applying gentle suction to the surface of the wound as it heals, is a relatively new treatment that has provided promising early results in patients with surgical wounds associated with major trauma.

However, a new study from NDORMS finds that the use of incisional negative pressure wound therapy, compared with standard wound dressing, resulted in no significant difference in the rate of deep surgical site infection (SSI).

Each year the NHS spends between £4.5 - £5.1bn* on wound management. Because of the extra cost of suction pumps NPWT costs an average of £149.52, compared to £1.87 for standard dressings**. Exact figures on the number of NPWT dressings currently being used in the NHS is difficult to estimate, according to researchers, but millions of standard dressings are used in the NHS each year, with NPWT also being increasingly used. The researchers are due to publish a further economic analysis of the treatments later this year.

Lead author Professor Matthew Costa said: "Negative pressure wound therapy offered the prospect of reducing patients' risk of wound infection. However, we needed to be sure about this because the new dressings are more expensive than the current standard care. In the largest study of its kind we found no evidence that negative pressure dressings reduced the risk of deep infection in the surgical wound. The negative pressure dressings were very unlikely to be cost effective. This is important because the NHS spends millions of pounds on wound dressings each year. Using less costly standard treatment will mean savings for the NHS without compromising patient outcomes."

Professor Jason Madan from Warwick Medical School was the lead health economist for the WHIST trial. He said: "If the NHS stays with standard treatment, patients will be just as healthy, and the money that would have been spent on negative pressure wound therapy can be used in other ways that do improve patients' health."

The randomised clinical trial included 1548 participants each given either NPWT, or standard wound dressing, and the primary outcome measure was deep surgical site infection at 30 days. The research found no significant difference in the infection rate in the NPWT group at 5.84% and in the standard dressing group at 6.68%.

Professor Hywel Williams, Director of the NIHR Health Technology Assessment (HTA) Programme, which funded the research, said: "When most people think of research they usually think of developing new cures and tech innovations, but this valuable study shows that research into existing innovations that are being increasingly used in the NHS can be just as important."

The results of the trial have been published in the Journal of the American Medical Association (JAMA).

The trial was supported by the NIHR Oxford Biomedical Research Centre and the NIHR Clinical Research Network.

Results of the study are also being considered by the National Wound Care Strategy Programme as part of their evidence-based recommendations in developing guidelines for the use of NPWT for the NHS.

* The annual cost to the NHS of managing patients with wounds is between £4.5 billion -£5.1 billion. Guest, J. F., Ayoub, N., Mcllwraith, T., Uchegbu, I., Gerrish, A., Weidlich, D., Vowden, K. & Vowden, P. 2015. Health economic burden that wounds impose on the National Health Service in the UK. Downloaded from http://bmjopen.bmj.com/ on January 4, 2016 - Published by group.bmj.com

** NHS Supply Chain Catalogue Jan 2019 (average)

Similar stories

COVID-19 vaccines shown to reduce infection by 90% in nursing homes

A new collaborative study between the Catalan Institute of Health, the Public Health Secreatariat of Catalonia, and the Centre for Statistics in Medicine, NDORMS, at the University of Oxford have confirmed that COVID-19 vaccines greatly reduce infections, hospitalisations and mortality for up to 6 months.

The Kennedy Institute completes its roof extension

Building work at the Kennedy Institute of Rheumatology has finished, providing a new third floor that houses additional meeting and collaboration space for data science and offices for the management of clinical trials.

Unlocking the secrets of the microbiome

Jethro Johnson, Deputy Director of the Oxford Centre for Microbiome Research explains how the centre is building a research community to understand the microbiome and harness its power to promote health and prevent disease.

Into the future: watching biology unfold

As part of the University of Oxford’s mission to provide its researchers with the newest state-of-the-art optical imaging equipment and as part of a strategic partnership with the Kennedy Institute of Rheumatology (KIR), the Institute of Developmental and Regenerative Medicine (IDRM), and Carl Zeiss AG (ZEISS), ZEISS has installed a ZEISS Lattice Lightsheet 7 microscope at the KIR.

New Botnar Research Institute Director starts today

Professor Jonathan Rees begins his new role as Director of the Botnar Research Institute today, taking over from Professor Andrew Carr.

Patient and public involvement in Rheumatology research – embracing the wave of change

On launching the new OPEN ARMS PPI group in Oxford, Dr. Laura Coates explored the patient and public involvement (PPI) models of three academic centres in the UK to show how it benefits researchers, clinicians, and patients alike.